Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m
Status:
Unknown status
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
The development of an innovative imaging agent capable of non-invasively detecting vulnerable
plaques is a major objective of research in cardiovascular pathology. Such a tool would allow
for better identification of patients at risk of acute events. We showed that 99mTechnetium
(99mTc)-labeled fucoidan was able to target P-selectine expressed by activated platelets in
vitro in humans and in vivo in a model of abdominal aortic aorta thrombus and endocarditic
vegetations in rats.
One of the objectives of the Nanoathero program is the clinical translation of the
99mTc-fucoidan. As a first step, we will assess the safety, biodistribution and dosimetry of
this new radiopharmaceutical in humans.